In vitro and in vivo studies on prostate cancer cell lines and tumor xenografts with varying basal PSMA expression levels and androgen dependencies showed an upregulation of PSMA by 1.5- to 25-fold following exposure to enzalutamide [28–30]. The gene discussed is FOLH1; the disease is prostate cancer.